8-K: Brainstorm Cell Therapeutics Appoints Dr. Hartoun Hartounian as Chief Operating Officer

Brainstorm Cell Therapeutics has appointed Dr. Hartoun Hartounian as its new Executive Vice President and Chief Operating Officer, effective June 24, 2024, to enhance operational efficiency and support the commercial readiness of its therapeutic platforms.

Summary

• Brainstorm Cell Therapeutics has appointed Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective June 24, 2024.
• Dr. Hartounian brings over 32 years of experience in the biopharmaceutical industry, with a focus on cell and gene therapy.
• He previously founded and led BioCentriq, which was acquired for $73 million in 2022.
• Dr. Hartounian's responsibilities will include overseeing all operational aspects of the company, including CMC and commercialization.
• His employment agreement includes an initial base annual salary of $450,000, an option to purchase 60,000 shares, and a one-time grant of 30,000 restricted shares.
• He is also eligible for an annual cash bonus of up to 35% of his base salary and a $10,000 signing bonus.

Sentiment

Score: 8

Explanation: The appointment of an experienced COO is a positive development for the company, suggesting a move towards operational readiness and commercialization. The sentiment is optimistic due to the executive's strong track record and the company's focus on advancing its therapies.

Positives

• Dr. Hartounian's extensive experience in cell and gene therapy is expected to enhance the company's operational efficiency.
• His track record of successfully leading and growing biotechnology companies is a significant asset.
• The appointment is seen as a step towards preparing for the commercialization of NurOwn for ALS.
• The compensation package includes incentives that align his interests with the company's success.

Risks

• The company's future success depends on the successful development and commercialization of NurOwn.
• The company's ability to raise additional capital is a potential risk.
• There are inherent uncertainties in the clinical development and regulatory approval process.

Future Outlook

The company is focused on advancing NurOwn, its investigational treatment for ALS, and preparing for its registrational Phase 3b study. The appointment of Dr. Hartounian is intended to support these efforts and enhance the company's operational efficiency and commercial readiness.

Management Comments

• Chaim Lebovits, President and CEO of Brainstorm Cell Therapeutics, stated that Dr. Hartounian's experience will be invaluable as they advance NurOwn.
• Dr. Hartounian stated he is eager to join Brainstorm and leverage his expertise in advancing the company's innovative therapies.

Industry Context

The appointment of a seasoned executive with experience in cell and gene therapy aligns with the growing focus on these modalities in the biopharmaceutical industry. This move suggests Brainstorm's commitment to strengthening its operational capabilities as it moves closer to potential commercialization of its therapies.

Comparison to Industry Standards

• The appointment of a COO with a strong background in cell and gene therapy is consistent with industry trends, as companies in this sector often seek leaders with specific expertise in manufacturing and commercialization.
• Dr. Hartounian's experience leading BioCentriq to a $73 million acquisition is a notable achievement, demonstrating his ability to create value in the CDMO space, which is a key area for companies developing cell and gene therapies.
• The compensation package, including a base salary, stock options, and bonuses, is typical for executive-level appointments in the biotech industry.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment positively, as it signals progress towards commercialization.
• Employees may benefit from Dr. Hartounian's leadership and experience.
• Patients with ALS may have increased hope for the availability of NurOwn.

Next Steps

• Dr. Hartounian will assume his role as COO on June 24, 2024.
• The company will continue to advance NurOwn through its Phase 3b study.
• The company will file the employment agreement as an exhibit to its Quarterly Report on Form 10-Q for the three months ended June 30, 2024.

Key Dates

Keywords

Chief Operating Officer, Hartoun Hartounian, Brainstorm Cell Therapeutics, cell therapy, gene therapy, NurOwn, ALS, biopharmaceutical, executive appointment, commercialization